Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.860
-0.010 (-0.53%)
At close: Sep 18, 2025, 4:00 PM EDT
1.860
0.00 (0.00%)
After-hours: Sep 18, 2025, 8:00 PM EDT
Protalix BioTherapeutics Revenue
Protalix BioTherapeutics had revenue of $15.66M in the quarter ending June 30, 2025, with 16.21% growth. This brings the company's revenue in the last twelve months to $61.95M, up 62.79% year-over-year. In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%.
Revenue (ttm)
$61.95M
Revenue Growth
+62.79%
P/S Ratio
2.26
Revenue / Employee
$290,836
Employees
213
Market Cap
148.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 53.40M | -12.10M | -18.47% |
Dec 31, 2023 | 65.49M | 17.86M | 37.48% |
Dec 31, 2022 | 47.64M | 9.29M | 24.22% |
Dec 31, 2021 | 38.35M | -24.55M | -39.03% |
Dec 31, 2020 | 62.90M | 8.21M | 15.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PLX News
- 7 days ago - Protalix BioTherapeutics to Present at Investor Summit Virtual - Accesswire
- 16 days ago - Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 24 days ago - Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp - Seeking Alpha
- 5 weeks ago - Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results - PRNewsWire
- 6 weeks ago - Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 - PRNewsWire
- 2 months ago - Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer - PRNewsWire
- 2 months ago - Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® - PRNewsWire